Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb 26:12:1179554918759079.
doi: 10.1177/1179554918759079. eCollection 2018.

Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach

Niamh Coleman  1 , Malaka Ameratunga  1 , Juanita Lopez  1
Affiliations
Review

Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach

Niamh Coleman et al. Clin Med Insights Oncol. .

Abstract

Over the past decade, precision cancer medicine has driven major advances in the management of advanced solid tumours with the identification and targeting of putative driver aberrations transforming the clinical outcomes across multiple cancer types. Despite pivotal advances in the characterization of genomic landscape of glioblastoma, targeted agents have shown minimal efficacy in clinical trials to date, and patient survival remains poor. Immunotherapy strategies similarly have had limited success. Multiple deficiencies still exist in our knowledge of this complex disease, and further research is urgently required to overcome these critical issues. This review traces the path undertaken by the different therapeutics assessed in glioblastoma and the impact of precision medicine in this disease. We highlight challenges for precision medicine in glioblastoma, focusing on the issues of tumour heterogeneity, pharmacokinetic-pharmacodynamic optimization and outline the modern hypothesis-testing strategies being undertaken to address these key challenges.

Keywords: Glioblastoma; high grade glioma; immunotherapy; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Molecular Characterisation of Glioblastoma.
Figure 2.
Figure 2.
Framework for precision cancer medicine for glioblastomas.
See this image and copyright information in PMC

References

    1. Hess KR, Broglio KR, Bondy ML. Adult glioma incidence trends in the United States, 1977-2000. Cancer. 2004;101:2293–2299. doi:10.1002/cncr.20621. - DOI - PubMed
    1. Thakkar JP, Dolecek TA, Horbinski C, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014;23:1985–1996. doi:10.1158/1055-9965.EPI-14-0275. - DOI - PMC - PubMed
    1. Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 2013;15:i1–i56. doi:10.1093/neuonc/not151. - DOI - PMC - PubMed
    1. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. Lancet. 2012;379:1984–1996. doi:10.1016/S0140-6736(11)61346-9. - DOI - PubMed
    1. Stupp R, Mason W, van den Bent MJ, et al. ; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005:987–996. doi:10.1056/NEJMoa043330. - DOI - PubMed

LinkOut - more resources